We are delighted to announce that we are back with the Season 3 of o2h ChaiTime .
We have all seen death rates decrease and vaccinations increase, does this mean that we are at the tailend of the pandemic? Well we all hope so; one of the trends that we have seen is certain industries to come through this stronger. The SPDR S&P Biotech ETF is making fresh highs; investors have been forced fed courses in epidemiology and biology and realize the importance of science on both the economy and society.
In this ChaiTime we were very excited for the opportunity to have an exclusive 1-1 interview with Dr Sam Fazeli, a senior analyst at Bloomberg. He is one the world's leading and most respected biotech analysts in London with a career in the sector that spans over 20 years.
Sam is a senior analyst and the EMEA head at a dynamic platform for in-depth research available on the Bloomberg Professional service at BI. Dr. Fazeli specializes in European pharmaceuticals and biotechnology.
A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector.